

West Virginia Pharmacy Services



Drug Utilization Review

3rd Quarter 2025

Prepared by :

g>inwell

Drug Utilization Review Board Meeting

10/22/2025

Disclaimer: This report is for trending purposes only and is not intended to match other financial reports

**DUR Quarterly Overall Summary Report**

WVDRGS044

Report Period from 07/01/2025 thru 09/30/2025

Categories	3rd Qtr 2025	3rd Qtr 2024	% Change
Total Paid Amount	\$258,255,418.68	\$244,351,524.56	5.69
Eligible Members	455,997	470,925	-3.17
Utilizing Eligibles	228,855	235,418	-2.79
Total # Prescriptions	1,957,660	1,991,826	-1.72
Cost per Utilizing Member	\$1,128.47	\$1,037.95	8.72
Average # Prescriptions per Utilizer	8	8	0.00
Average Cost per Prescription	\$131.92	\$122.68	7.53
# Generic Prescriptions	1,711,250	1,725,551	-0.83
% Generic Prescriptions	87	86	1.16
Total Cost - Generics	\$38,215,538.98	\$36,269,693.03	5.36
Average Generic Prescription Cost	\$22.33	\$21.02	6.25
Average Days Supply - Generics	32	32	0.00
# Brand Prescriptions	246,410	266,275	-7.46
% Brand Prescriptions	12.00	13.00	-7.69
Total Cost - Brand	\$220,039,879.70	\$208,081,831.53	5.75
Average Brand Prescription Cost	\$892.98	\$781.45	14.27
Average Days Supply - Brand	26	25	4.00
Rebates Collected	\$163,382,443.01	\$163,262,260.37	0.07



WVDRGS050

Top 25 Therapeutic Classes By Prescription Count

Report Period from 07/01/2025 thru 09/30/2025

Reporting Months (3rd Quarter) 07/01/2025 - 09/30/2025

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONVULSANTS	H4B	96,639	4.90	\$4,870,275.13
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	89,258	4.50	\$23,511,768.22
3	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	77,266	3.90	\$908,709.37
4	PROTON-PUMP INHIBITORS	D4J	64,017	3.20	\$986,155.18
5	ANTIHISTAMINES - 2ND GENERATION	Z2Q	63,362	3.20	\$833,170.67
6	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB (STATINS)	M4D	53,273	2.70	\$633,260.04
7	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	S2B	50,712	2.60	\$638,740.70
8	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	48,466	2.40	\$1,774,816.61
9	VITAMIN D PREPARATIONS	C6D	47,305	2.40	\$460,786.32
10	BETA-ADRENERGIC BLOCKING AGENTS	J7C	38,970	2.00	\$536,734.07
11	ANTIHISTAMINES - 1ST GENERATION	Z2P	38,434	1.90	\$507,121.50
12	PENICILLIN ANTIBIOTICS	W1A	37,424	1.90	\$514,735.47
13	ANTIPSYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGNST	H7T	36,564	1.80	\$5,685,183.77
14	GLUCOCORTICOIDS	P5A	34,839	1.80	\$1,125,898.12
15	SKELETAL MUSCLE RELAXANTS	H6H	33,207	1.70	\$440,626.91
16	ANTIEMETIC/ANTIVERTIGO AGENTS	H6J	30,795	1.60	\$471,560.66
17	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	28,764	1.50	\$481,601.02
18	ANTI-ANXIETY DRUGS	H2F	28,066	1.40	\$378,496.36
19	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	28,003	1.40	\$2,401,584.10
20	ANTIHYPERTENSIVES, ACE INHIBITORS	A4D	27,850	1.40	\$319,123.55
21	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	27,679	1.40	\$2,990,694.15
22	THYROID HORMONES	P3A	26,852	1.40	\$499,182.27
23	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	H7E	26,540	1.30	\$310,969.32
24	ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPAGONIST)	C4I	25,761	1.30	\$23,573,029.00
25	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	24,820	1.30	\$715,594.61
Totals:			1,084,866	54.90	\$75,569,817.12




WVDRGS027

WV POS Quarterly Drug Class Review Top 12 by Rx Count

Reporting Period From: 07/01/2025 - 09/30/2025

Reporting Months (3rd Quarter): 07/01/2025 - 09/30/2025

Top 12 Therapeutic Classes By Prescription Count**Amount Paid**

ANTICONVULSANTS	\$4,870,275.13
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	\$23,511,768.22
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$908,709.37
PROTON-PUMP INHIBITORS	\$986,155.18
ANTIHISTAMINES - 2ND GENERATION	\$833,170.67
ANTHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(STATINS)	\$633,260.04
NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	\$638,740.70
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	\$1,774,816.61
VITAMIN D PREPARATIONS	\$460,786.32
BETA-ADRENERGIC BLOCKING AGENTS	\$536,734.07
ANTIHISTAMINES - 1ST GENERATION	\$507,121.50
PENICILLIN ANTIBIOTICS	\$514,735.47



WVDRGS029

Top 25 Therapeutic Classes by Amount Paid

Report Period from 07/01/2025 thru 09/30/2025

Reporting Months (3rd Quarter): 7/1/2025-09/30/2025

Rank	Therapeutic Class	Therapeutic Class Codes	Amount Paid	% of Total Amount Paid	Prescription Count
1	ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR AGONIST)	C4I	\$23,573,029.00	9.10	25,761
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	\$23,511,768.22	9.10	89,258
3	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$17,013,059.50	6.60	2,048
4	ANTIHYPERGLYCEMIC-SODIUM GLUC COTRANSPORT2(SGLT2) INH	C4D	\$10,308,004.27	4.00	12,133
5	CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	B0F	\$8,298,330.90	3.20	322
6	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$6,525,709.27	2.50	490
7	ANTIPSORIATIC AGENTS,SYSTEMIC	L1A	\$5,730,423.54	2.20	600
8	ANTIPSYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGNIST	H7T	\$5,685,183.77	2.20	36,564
9	DIRECT FACTOR XA INHIBITORS	M9V	\$5,416,248.40	2.10	7,979
10	INSULINS	C4G	\$5,180,114.79	2.00	21,297
11	ANTICONVULSANTS	H4B	\$4,870,275.13	1.90	96,639
12	ARV-NUCLEOSIDE,NUCLEOTIDE RTI,INTEGRASE INHIBITORS	W5X	\$4,802,197.78	1.90	1,216
13	HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMB	W0E	\$4,635,385.56	1.80	371
14	ANTIPSYCHOTIC-ATYPICAL,D3/D2 PARTIAL AG-5HT MIXED	H8W	\$4,580,597.03	1.80	3,265
15	BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	B63	\$4,409,252.36	1.70	19,088
16	INTERLEUKIN-4(IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	V4D	\$4,242,991.47	1.60	1,038
17	DIABETIC SUPPLIES	Y9A	\$3,882,654.51	1.50	9,303
18	HEMOPHILIA TREATMENT AGENTS,NON-FACTOR REPLACEMENT	M0P	\$2,991,324.50	1.20	79
19	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	H2V	\$2,990,694.15	1.20	27,679
20	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$2,901,541.09	1.10	14,488
21	ANTIMIGRAINE PREPARATIONS	H3F	\$2,758,641.35	1.10	11,920
22	HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	W0B	\$2,740,919.05	1.10	386
23	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$2,401,584.10	0.90	28,003
24	IBS-C/CIC AGENTS, GUANYLATE CYCLASE-C AGONIST	D6G	\$2,379,074.75	0.90	3,326
25	HUMAN INTERLEUKIN 12/23 (IL-12/13) INHIBITORS, MAB	Z2U	\$2,293,929.78	0.90	93
	Totals:		\$164,122,934.27	63.60	413,346




WVDRGS030

Top 12 Therapeutic Classes by Amount Paid

Reporting Months 3rd Quarter: 7/1/2025-09/30/2025

Reporting Months (3rd Quarter): 7/1/2025-09/30/2025

Top 12 Therapeutic Classes by Amount Paid**Prescriptions**

ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPT.AGONIST)	25,761
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	89,258
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	2,048
ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT2(SGLT2) INH	12,133
CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	322
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	490
ANTIPSORIATIC AGENTS,SYSTEMIC	600
ANTIPSYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGNST	36,564
DIRECT FACTOR XA INHIBITORS	7,979
INSULINS	21,297
ANTICONVULSANTS	96,639
ARV-NUCLEOSIDE,NUCLEOTIDE RTI,INTEGRASE INHIBITORS	1,216



Pharmacy Generic Utilization Summary by Amount Paid


WVDRGS034

Reporting Month 3rd Quarter: 7/1/2025-09/30/2025

Reporting Months (3rd Quarter): 7/1/2025-09/30/2025

Generic Utilization Summary

by Amount Paid



	BNG	\$176,661,767	68.3 %
	BWG	\$43,468,577	16.8 %
	GEN	\$38,539,108	14.9 %
	Total	\$258,669,452	100.0 %

BNG = Brand With no Generic Available

BWG = Brand Dispensed when Generic Available

GEN = Generic



WVDRGS033


Pharmacy Generic Utilization Summary By Number Of Prescriptions

Report Period from 07/01/2025 thru 09/30/2025

Reporting Months (3rd Quarter): 7/1/2025-09/30/2025

Generic Utilization Summary

by Number of Prescriptions

*BNG = Brand With no Generic Available**BWG = Brand Dispensed when Generic Available**GEN = Generic*




WVDRGS035

Pharmacy DUR Savings - QUARTERLY

Report Period from 07/01/2025 thru 09/30/2025

Reporting Months (3rd Quarter) : 7/1/2025 - 9/30/2025



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$1,226,449.85	2.00
ER	Early Refill	\$31,971,715.57	59.00
HD	High Dose	\$1,028,749.16	2.00
ID	Ingredient Duplication	\$1,957,929.31	4.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$374,233.15	1.00
TD	Therapeutic Duplication	\$17,338,728.92	32.00
Totals:		\$53,897,805.97	100.00